Stockholm, Sweden and Helsinki, Finland — Stratipath, a pioneer in AI-based precision diagnostics, today announced that Helsinki University Hospital (HUS), Finland’s largest healthcare provider and one of the leading academic medical centres in the Nordics, has chosen to implement Stratipath Breast, an AI-based risk profiling solution for breast cancer, as a tool for prognostic testing in its clinical environment.
Under the agreement, HUS is implementing Stratipath Breast for prognostic risk profiling in breast cancer, with the aim of evaluating its clinical impact on treatment decision-making within HUS’s oncology workflows. The evaluation will be conducted in parallel with the traditional diagnostic approach, assessing how AI-based risk profiling can strengthen and advance conventional clinical decision-making, with the objective of supporting full implementation in routine clinical practice.
“Helsinki University Hospital continuously seeks to adopt new technologies that improve diagnostic precision and patient care,” said Anders Ståhls, Head Physician, Pathology department at HUS. “Implementing Stratipath Breast gives us the opportunity to evaluate how AI-based prognostic risk profiling can support faster, more individualised treatment decisions for the patients.”
Stratipath Breast is the first CE-IVD marked AI-based solution for prognostic risk profiling of breast cancer using routine histopathology slides. It provides an alternative to traditional gene expression tests, which are often associated with high costs, long turnaround times, and limited accessibility. Stratipath Breast delivers results within one hour, ready to support clinical decisions at the tumour board.
“We are very pleased to collaborate with HUS, one of the most respected academic hospitals in the Nordic region, which makes it an ideal setting for evaluating the real-world clinical impact of AI-based prognostic risk profiling”, said Annica Jämtén Ericsson, COO of Stratipath. “Together, we aim to generate evidence that supports broader adoption of precision diagnostics in everyday care.”
“This collaboration with HUS reflects our core mission, to make precision diagnostics available to more patients,” said Prof. Johan Hartman, Chief Medical Officer and Co-founder of Stratipath. “With Stratipath Breast, we provide physicians with the tools they need to make more informed treatment decisions, while delivering results at a fraction of the time and cost of traditional gene expression profiling.”
This agreement further strengthens Stratipath’s presence across the Nordic region and marks another step in translating AI-based innovation in precision oncology into real-world clinical benefit.